{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:47:16Z","timestamp":1793652436645,"version":"4.5.1"},"reference-count":41,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2023,11,2]]},"DOI":"10.1080\/14712598.2023.2267975","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T10:52:44Z","timestamp":1696589564000},"page":"1103-1111","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":36,"title":["Managing adverse events of sacituzumab govitecan"],"prefix":"10.1080","volume":"23","author":[{"given":"Ilana","family":"Schlam","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Tufts Medical Center, Boston, MA, USA"},{"name":"Department of Medicine, Tufts University, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Tarantino","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA, USA"},{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.3014"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1369\/0022155411410430"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10076-7"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00470-8"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12966"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14686"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000629"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00467-1"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814213"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.1071"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.002"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1001"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.004"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01002"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.1003"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03489"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS619"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS1106"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1860"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0644-7"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00624"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30789"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.1033"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101383"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00269"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw325"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1100-9"},{"key":"e_1_3_5_34_1","unstructured":"Cochrane handbook for Systematic Reviews of Interventions (version 5.1.0). 8.5 the cochrane Collaboration\u2019s tool for assessing risk of bias. https:\/\/handbook-5-1.cochrane.org\/chapter_8\/table_8_5_a_the_cochrane_collaborations_tool_for_assessing.htm"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4089"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz278"},{"key":"e_1_3_5_37_1","unstructured":"Initial results from phase 2 trial demonstrate potential of trilaciclib to reduce adverse events related to an antibody drug conjugate (ADC). News Release. G1 Therapeutics Inc. Nov 2 2022. [cited 2023 Jul 7]. Available from: http:\/\/bit.ly\/3DUA6rO"},{"key":"e_1_3_5_38_1","unstructured":"TRODELVY. Prescribing information. 2020. [cited 2023 Jul 11]. Available from: https:\/\/trodelvy.com\/pdf\/PrescribingInformation.pdf"},{"key":"e_1_3_5_39_1","unstructured":"Antiemesis NCCN clinical practice guidelines in Oncology (NCCN guidelines\u00ae) version 22023. [cited 2023 7]."},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.31_suppl.216"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.20939"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS619"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1859"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2023.2267975","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T23:34:58Z","timestamp":1727220898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2023.2267975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,2]]}},"alternative-id":["10.1080\/14712598.2023.2267975"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2023.2267975","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-07-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}